Calumet (NASDAQ:CLMT) +1.9% pre-market Tuesday after providing preliminary Q4 financial results, expecting to report a net loss in the $24M-$54M range and adjusted EBITDA of $45M-$60M.
The company also forecasts FY 2025 capital spending of $50M-$70M in its specialties business and $10M-$20M of maintenance